Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Net Margin (2016 - 2025)

Historic Net Margin for Viridian Therapeutics, Inc.\DE (VRDN) over the last 12 years, with Q3 2025 value amounting to 49.67%.

  • Viridian Therapeutics, Inc.\DE's Net Margin rose 888968400.0% to 49.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 427.3%, marking a year-over-year increase of 846352800.0%. This contributed to the annual value of 89387.09% for FY2024, which is 136756200.0% down from last year.
  • As of Q3 2025, Viridian Therapeutics, Inc.\DE's Net Margin stood at 49.67%, which was up 888968400.0% from 134313.33% recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's Net Margin's 5-year high stood at 49.67% during Q3 2025, with a 5-year trough of 134313.33% in Q2 2025.
  • Moreover, its 5-year median value for Net Margin was 66194.44% (2023), whereas its average is 53169.89%.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Net Margin tumbled by -649564700bps in 2023, and later surged by 888968400bps in 2025.
  • Viridian Therapeutics, Inc.\DE's Net Margin (Quarter) stood at 13526.17% in 2021, then tumbled by -222bps to 43604.76% in 2022, then tumbled by -113bps to 92861.11% in 2023, then decreased by -19bps to 110809.72% in 2024, then soared by 100bps to 49.67% in 2025.
  • Its Net Margin was 49.67% in Q3 2025, compared to 134313.33% in Q2 2025 and 120711.11% in Q1 2025.